Comparatively, Perepelyuk and colleagues [252] synthesized a hybridized nanoparticle with a MUC1-aptamer for targeting delivery of miR-29b to NSCLC cells expressing MUC1, a transmembrane protein that is aberrantly expressed by cancer cells. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.